GENLIGHT CONSULTING

GENLIGHT CONSULTING

Consulting

GenLight Consulting, Inc. (GLCI) is providing genetic consulting services to practicing physicians and patients designed to assist in: 

a) Understanding the individuals' risk of developing common human disorders based on comprehensive assessment of unique sets of genetic and genomic markers of disease predisposition;

b) Analysis and interpretation of the high complexity patterns of the individual's genetic & genomic features affecting heath, ageing, longevity, and disease predisposition profiles; and 

c) Implementation of the concept of individualized, genomics-guided lifestyle and dietary adjustments, health maintenance, and long-term disease management by matching the individual's genetic & genomic profiles with predicted therapeutic benefits and potential side effects of specific drugs and drug combinations.  

 

CLINICAL TRIALS

We will provide up-to-date information on ongoing clinical trials to facilitate the assistance in considerations for potential enrollment into clinical trials scientific profiles of which are most likely to provide benefits for individual patients. This service includes an expert advice on meeting the criteria for enrollment and open-enrollment periods.

 

DURING THE INITIAL CONSULTATION WE WILL CUSTOM-DESIGN THE PORTFOLIO OF CONCIERGE-LEVEL GENOMICS-GUIDED MEDICAL SERVICES THAT SPECIFICALLY ADDRESSES YOUR INDIVIDUAL NEEDS AND BUDGETARY CONSTRAINS.

 

We provide services assisting our customers to find high-quality health care providers based on past performance, therapy outcomes, and cost comparisons data.

 

GenLight Diagnostics & GenLight Therapeutics Divisions

 

NEW: We are offering a broad range of proprietary products and services to assist healthy people in understanding the individual's genetic risk of developing common human disorders.

 

Additional product and services are offered by GenLight Diagnostics and GenLight Therapeutics Divisions. Please follow the corresponding links for details.

 
We will help to measure, calculate, evaluate, and understand your individual genetic risk of developing common human disorders.

If desired, we will be able to perform this analysis for all your family members, including your children and your future offspring.

We will assess your individual genetic risk factors for developing the following major common human disorders:    

Alzheimer’s disease (AD)

Autism Spectrum Disorders (ASD)

Bipolar disease (BD)

Rheumatoid arthritis (RA)

Coronary artery disease (CAD)

Crohn's disease (CD)

Type 1 diabetes (T1D)

Type 2 diabetes (T2D)

Obesity (OB)

Hypertension (HT)

Ankylosing spondylitis (AS)

Graves' disease (autoimmune thyroid disease; AITD);

Multiple sclerosis (MS);

Breast cancer (BC);

Prostate cancer (PC);

Lung cancer (LC);

Ovarian cancer (OC);

Melanoma (MEL);

Parkinson’s disease (PD);

Systemic lupus erythematosus (SLE)

Vitiligo (VIT)

Huntington’s disease (HD)

Ulcerative colitis (UC)

Multiple autoimmune diseases (MAD)

 

GenLight Technologies Corporation, Inc. (GLTCI)

GENLIGHT THERAPEUTICS

GENLIGHT THERAPEUTICS

Therapeutics

GenLight Therapeutics, Inc. (GLTI) is developing individualized target-tailored biological and small molecule therapeutics specifically targeting disease phenotypes resistant to existing, broadly utilized in current clinical practice standard therapeutic protocols.

Underlying scientific concept of the GLTI’s drug development program is based on design of drug combinations targeting individual’s disease gene expression profiles and causing transcriptional reversal of disease phenotypes. Main focus of the GLTI’s anti-cancer drug development program is design of biological and small molecule therapeutics targeting cancer stem cell phenotypes. As an important component of individualized therapy selection and prescription assistance and advisory services, GLTI is ready to provide the services of design and maintenance of individualized models of human disease, including humanized mouse models of cancer for individual patients. These individualized patient-derived disease models will be used for evaluation of the efficiency of new therapies in real time, before selecting and administering next-in-line treatments to patients. Individualized, patient-based tumor models will be used for continuous assessment of the therapeutic utility of NEW drugs and drug combinations specifically designed against genetic targets of therapy-resistant disease phenotypes. 
 

GenLight Consulting Corporation & GenLight Diagnostics Corporation

Multiple products and services essential for practical implementation of the concept of individualized genomics-guided therapies are offered by GenLight Diagnostics, Inc. and GenLight Consulting, Inc. and would allow a prediction of the effectiveness and safety of individualized target-tailored therapy in real time. For example, to assist cancer patients we will use the proprietary individualized experimental models of the disease generated by implanting tumor cells from the patient in orthotopic organs of humanized mouse. Various therapies or combinations of therapy can be tested in these individualized models to select in real time most efficient therapeutic modalities and regimens.

GenLight Consulting, Inc. is offering genetic consulting services designed to assist practicing physicians and patients. A medical doctor from GenLight Consulting will review all of the patient’s genetic data obtained from GenLight Diagnostics, Inc. or other sources with the patient and/or physician and help him or her select the best possible cancer treatment and personalized approaches to disease management.

 

NEW: We are offering a broad range of proprietary products and services to assist healthy people in understanding the individual's genetic risk of developing common human disorders.

 
We will help to measure, calculate, evaluate, and understand your individual genetic risk of developing common human disorders.

If desired, we will be able to perform this analysis for all your family members, including your children and your future offspring.

We will assess your individual genetic risk factors for developing the following major common human disorders:    

Alzheimer’s disease (AD)

Autism Spectrum Disorders (ASD)

Bipolar disease (BD)

Rheumatoid arthritis (RA)

Coronary artery disease (CAD)

Crohn's disease (CD)

Type 1 diabetes (T1D)

Type 2 diabetes (T2D)

Obesity (OB)

Hypertension (HT)

Ankylosing spondylitis (AS)

Graves' disease (autoimmune thyroid disease; AITD);

Multiple sclerosis (MS);

Breast cancer (BC);

Prostate cancer (PC);

Lung cancer (LC);

Ovarian cancer (OC);

Melanoma (MEL);

Parkinson’s disease (PD);

Systemic lupus erythematosus (SLE)

Vitiligo (VIT)

Huntington’s disease (HD)

Ulcerative colitis (UC)

Multiple autoimmune diseases (MAD)

 

GenLight Technologies Corporation, Inc. (GLTCI)

 

GENLIGHT DIAGNOSTICS

GENLIGHT DIAGNOSTICS

Diagnostics

GenLight Diagnostics, Inc. (GLDI) is conducting genetic, genomic, and molecular diagnostic evaluations to assist both practicing physicians and patients. Our proprietary panels of disease-specific laboratory tests are custom designed to extract the essential information regarding the individual’s genetic disease profiles and likelihood of failure or cure after applications of existing therapeutic protocols.

NEW OFFERS: We offer proprietary products and services for individualized HEALTH MANAGEMENT. This service is designed to assist healthy people in understanding their individual genetic risk of developing common human disorders. We will provide custom-tailored recommendations for lifestyle, diet, and exercise adjustments which are designed to decrease the likelihood of disease development and progression.

GenLight Diagnostics cancer management services entail microarray-based and Q-PCR-based genomic and genetic tests integrating multiple cancer therapy outcome predictor (CTOP) gene signatures. CTOP gene signatures are designed for cancer therapy outcome prediction and assessment of long-term disease prognosis. This information will be used to stratify patients diagnosed with prostate, breast, lung, or ovarian cancers into sub-groups with statistically distinct clinical outcomes after initial standard therapy:

(1) patients with therapy-responsive cancers (patients with high probability of a cure with existing cancer therapies) and

(2) patients with therapy-resistant cancers (patients with high probability of therapy failure and disease relapse after application of standard therapeutic protocols).

This stratification approach has been validated by retrospective analyses of large databases of breast and prostate tumors from patients with known long-term therapy outcomes after treatment in several independent Institutions worldwide. Currently, these tests can be completed using tumor tissue samples.

In the future, GenLight Diagnostics will conduct blood and urine tests for diagnosis, prognosis, and therapy outcome prediction. These new assays are being developed by Dr. Glinsky’s lab and will be licensed to GenLight Diagnostics once they are fully developed and validated.

Additional algorithms and gene signatures are at various development and validation stages for diagnosis, risk stratification, therapy selection, and treatment outcome predictions for other cancers, such pancreatic and colon cancers.

We will help to measure, calculate, evaluate, and understand your individual genetic risk of developing common human disorders.

If desired, we will be able to perform this analysis for all your family members, including your children and your future offspring.

We will assess your individual genetic risk factors for developing the following major common human disorders:


Alzheimer’s disease (AD)

Autism Spectrum Disorders (ASD)

Bipolar disease (BD)

Rheumatoid arthritis (RA)

Coronary artery disease (CAD)

Crohn's disease (CD)

Type 1 diabetes (T1D)

Type 2 diabetes (T2D)

Obesity (OB)

Hypertension (HT)

Ankylosing spondylitis (AS)

Graves' disease (autoimmune thyroid disease; AITD);

Multiple sclerosis (MS);

Breast cancer (BC);

Prostate cancer (PC);

Lung cancer (LC);

Ovarian cancer (OC);

Melanoma (MEL);

Parkinson’s disease (PD);

Systemic lupus erythematosus (SLE)

Vitiligo (VIT)

Huntington’s disease (HD)

Ulcerative colitis (UC)

Multiple autoimmune diseases (MAD)

 

GenLight Technologies Corporation, Inc. (GLTCI)